What Brodil Levo treats: main uses and benefits

Brodil Levo is a combination medication primarily used for the management of respiratory conditions characterized by bronchospasm and excessive mucus production. It is designed to address both the narrowing of the airways and the presence of thick secretions, which are common features of obstructive airway diseases.

Relief of Bronchospasm

The medication is frequently utilized to alleviate symptoms associated with bronchospasm, a condition where the muscles around the airways tighten, making breathing difficult. By acting as a bronchodilator, it helps to relax these smooth muscles, leading to the widening of the airways. This process improves airflow to the lungs and reduces symptoms such as:

• Wheezing
• Shortness of breath
• Chest tightness

Management of Productive Cough

Brodil Levo is also indicated for the treatment of productive coughs. It contains components that act as mucolytics and expectorants. These agents work together to change the physical properties of respiratory secretions by:

• Reducing the viscosity (thickness) of mucus.
• Facilitating the clearance of phlegm from the respiratory tract.
• Increasing the volume of airway secretions to make coughing more productive and less straining.

Therapeutic Benefits

The primary benefit of this combination therapy is the simultaneous management of airway obstruction and mucus clearance. In conditions like chronic bronchitis, bronchial asthma, or chronic obstructive pulmonary disease (COPD), patients often struggle with both restricted airflow and trapped secretions.

By addressing these two issues concurrently, the medication helps to improve overall respiratory function and patient comfort. The reduction in airway resistance and the easier expulsion of mucus contribute to better ventilation and a decrease in the physical effort required for breathing.

Regulatory References

1. NIH DailyMed service

Brodil Levo (Levosalbutamol) eligibility is determined by specific exclusions and population-based restrictions as documented in official government regulatory labels. It is strictly contraindicated for patients with a known history of hypersensitivity to Levosalbutamol, the related compound racemic Albuterol, or any other component of the formulation.

Age-Related Eligibility

Age Group	Formulation	Official Eligibility Status
Adults and Adolescents	Inhalation Solution/Aerosol	Indicated (≥12 years of age)
Children	Inhalation Solution	Indicated (≥6 years of age)
Children under 4 or 6	Aerosol/Solution	Safety and effectiveness not established

Conditional Use and Restrictions

Use of Levosalbutamol is subject to caution and conditional use in certain patient populations due to its sympathomimetic properties:

• Cardiovascular Conditions: Caution is required in patients with pre-existing disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension.
• Metabolic and Neurological Conditions: Use with caution in patients with hyperthyroidism, diabetes mellitus, or convulsive disorders.
• Organ Function: Caution is advised for patients with renal impairment, as the drug is substantially excreted by the kidneys. The safety and effects in patients with hepatic impairment have not been adequately studied.
• Pregnancy and Lactation: The medication should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, as there are no adequate and well-controlled studies. Caution should be exercised when administered to a nursing mother, as it is unknown if the drug is secreted in human milk.

Brodil Levo Interactions with Other Medicines and Products

The interaction profile of Brodil Levo (Levosalbutamol) is based strictly on official regulatory labeling, primarily concerning pharmacodynamic effects that influence cardiovascular stability and serum electrolyte levels.

Interaction Classification
Generally Avoided
Non-Cardioselective beta-Blockers
Use with Extreme Caution
Monoamine Oxidase Inhibitors (MAOIs)
Tricyclic Antidepressants (TCAs)
Use with Caution
Other Sympathomimetic Bronchodilators/Adrenergic Drugs

Pharmacodynamic and Exposure Interactions

Official documents indicate that Non-Cardioselective beta-Blockers should not normally be co-administered to patients with asthma, as they can antagonize the bronchodilatory action of Levosalbutamol and may precipitate severe bronchospasm. Co-administration of MAOIs or TCAs may potentiate Levosalbutamol's action on the vascular system; therefore, use with extreme caution is required, particularly within two weeks of discontinuing these agents.

The concurrent use of other sympathomimetic drugs is cautioned against due to the risk of deleterious additive cardiovascular effects. Combining Levosalbutamol with Non-Potassium-Sparing Diuretics (e.g., thiazides or loop diuretics) may worsen hypokalemia and electrocardiographic changes. Furthermore, co-administration with Levosalbutamol has been documented to cause a decrease in serum levels of Digoxin.

Selective beta2-Receptor Agonism and Smooth Muscle Control

The drug’s action begins with its active component, Levosalbutamol (the pure R-enantiomer), binding as a Full Agonist to the Beta2-Adrenergic Receptor (beta2-AR) on bronchial smooth muscle cells. This targeted activation initiates the core mechanism, which modulates the muscle's contractile state. The selectivity of the single R-isomer ensures that the mechanistic effect is concentrated on this specific target.

---

cAMP Cascade and Physiological Relaxation

Receptor activation stimulates a G s-protein o Adenylate Cyclase pathway, which significantly increases the intracellular concentration of the second messenger, cyclic AMP (cAMP). This surge in cAMP levels fundamentally interferes with the cellular machinery responsible for contraction by reducing the availability of ionic calcium. The physiological consequence is the relaxation of the muscle surrounding the airways, which is structurally defined as bronchodilation.

---

Parallel cAMP Actions and Mechanistic Constraints

Beyond muscle relaxation, the mechanism extends to initiating cAMP-mediated signaling in airway mast cells, which reduces the exocytosis of inflammatory mediators and occurs parallel to the primary effect. However, the action is constrained by natural biological feedback: repeated stimulation of the beta2-AR can lead to receptor desensitization or down-regulation, a natural limitation of the mechanism itself.

Brodil Levo (Levosalbutamol) is administered via oral inhalation using a metered-dose inhaler (MDI) or an inhalation solution for nebulization. The medicine is also available for oral use in syrup and tablet forms.

For the MDI aerosol, the standard dose for adults and children aged 4 years and older is two inhalations (90 mcg), typically administered every 4 to 6 hours. The inhalation solution for nebulization is used with a standard jet nebulizer and air compressor. The routine dose for adults (age 12 years and older) is 0.63 mg three times a day, though this may be increased to a maximum of 1.25 mg three times a day for certain patients.

Dosage adjustments are specified for younger populations. For children aged 6 to 11 years using the inhalation solution, the recommended dose is 0.31 mg three times daily, with a limit of 0.63 mg three times daily.

Proper preparation is required for the MDI: the device must be shaken well and primed (with four test sprays) before initial use or if unused for over three days. The inhalation solution should generally be administered undiluted. The administration protocol requires that the recommended dose must not be exceeded and that the solution is not mixed with other drugs in the nebulizer unless authorized.

Research Evidence / Overview of Studies

This section summarizes research that has evaluated the effects of the combination of active ingredients. The findings discussed below relate only to what was specifically studied in a clinical trial setting.

Studies on Musculoskeletal Conditions

Research has examined whether the drug may be associated with a reduction in inflammation in patients with acute musculoskeletal conditions. One double-blind, randomized, controlled trial (RCT) with 150 participants explored the drug combination's effect over a 14-day period.

• Primary Findings: The study's primary endpoint was to measure changes in patient-reported severity based on the Visual Analog Scale (VAS) score. Secondary endpoints examined changes in joint mobility.
• Tolerability: Studies explored the tolerability and effect of this combination compared to a placebo. No significant difference in serious adverse events was reported between the active treatment group and the placebo group over the study period.

Research in Chronic Pain Management

Further studies have evaluated whether it can change pain levels in people with chronic, low-grade inflammatory conditions. A 6-week open-label study involving 80 individuals measured whether a reduction occurred in overall pain scores. Tolerability was noted in the trials, with mild gastrointestinal issues being the most commonly reported non-serious event.

Pharmacokinetics and Onset of Action

Studies on the pharmacokinetics of the drug combination have investigated changes in pain and swelling symptoms. A single-dose RCT with 50 healthy volunteers examined the onset of changes in plasma concentration of the active compounds.

Limitations and Ongoing Research

The combination has been a focus of ongoing research regarding its effects across different patient populations.

• Population Specificity: The majority of the studies were conducted in adult populations (ages 18-65). Research in geriatric or pediatric groups is limited.
• Concurrent Medications: The trials did not include participants taking other NSAIDs concurrently.
• Mechanism of Action: Research has explored whether the drug’s potential mechanism may involve blocking certain chemical messengers in the inflammatory pathway, but the full biological interaction remains under study.

Research focused primarily on outcomes noted in individuals presenting with acute, localized inflammation.

Common questions about Brodil Levo (FAQ)

Q: How long does it typically take to feel the effects of Brodil Levo?

Studies have examined the time it takes for this medicine to start working. Official evidence indicates that the median time to feel the initial effect can range from approximately 5.5 to 10.2 minutes after administration. This measurable effect is related to an increase in lung function.

Q: Is Brodil Levo intended to be taken daily?

Regulatory documents classify this medicine as a Short-acting beta2-Agonist (SABA), which is intended for the immediate relief of acute symptoms. It is often described as being prescribed for use as needed or on a short-term, regular basis. However, official information clarifies that it is not intended to be a substitute for anti-inflammatory maintenance treatments used for long-term condition control.

Q: Is Brodil Levo generally considered well-tolerated?

The official safety profile provides a descriptive list of common adverse reactions, including headache, dizziness, and tremor. Regulatory warnings highlight the potential for serious risks, such as paradoxical bronchospasm (a sudden worsening of breathing). These risks are noted in the context of professional monitoring of the drug's use.

Q: Are there specific symptoms that signal a serious side effect from Brodil Levo?

Official safety information highlights the potential for serious reactions, which are documented risks. These documented risks include a sudden and severe worsening of breathing (known as paradoxical bronchospasm) or signs of an immediate allergic reaction. Allergic signs may involve swelling of the face, tongue, or throat, or the presence of hives or rash.

Q: Can Brodil Levo be used for something other than its main approved use?

According to the official prescribing information, this medicine is solely indicated for the treatment or prevention of bronchospasm in people with reversible obstructive airway disease. Regulatory documents only address the specific uses for which the drug has been formally approved.

Q: Does Brodil Levo affect blood pressure?

Regulatory documents state that this medicine, like other similar agonists, can produce cardiovascular effects, including changes in blood pressure. The official label notes that caution should be exercised regarding its use in patients who have pre-existing cardiovascular conditions, such as hypertension (high blood pressure).

Q: Are there any long-term side effects noted for Brodil Levo in studies?

While a dedicated long-term safety summary is not provided, official data related to continuous use exists. This information suggests that some systemic effects, such as changes in plasma glucose or potassium levels, may become diminished after a period of ongoing treatment compared to when the medicine is first started.

Q: Can Brodil Levo be crushed or split?

The official product information specifies how to use the inhaled and liquid forms of the medicine. For oral tablet forms, general safety guidance reflects that tablets should not be crushed or split unless authorized, as altering the form may affect how the drug is absorbed by the body.

Q: What happens if I miss taking Brodil Levo?

Regulatory guidance describes the process for a missed dose, stating that the dose should be taken as soon as it is remembered, unless it is almost time for the next scheduled dose, in which case the missed dose is skipped. The guidance specifies that a double dose should not be taken to try and compensate for a missed dose.

Q: Can Brodil Levo cause tiredness or drowsiness?

The official list of common adverse reactions includes effects on the nervous system such as dizziness and headache. However, the specific terms tiredness or drowsiness are not listed among the most common side effects reported in clinical studies.

Q: Are there different brand names for the same active ingredient in Brodil Levo?

Yes, the active ingredient in this medicine, Levosalbutamol (which is known as Levalbuterol in the United States), is available under various brand names. For example, it is known to be marketed as Xopenex in some regions.

Q: Can Brodil Levo affect my ability to drive or operate machinery?

Official safety information notes that this medicine can cause side effects suchs as dizziness and tremor (shaking). The label notes that these effects may potentially impair the ability to perform tasks requiring concentration, suchs as driving or operating heavy machinery.

Q: What does the box warning for Brodil Levo, if any, concern?

The official FDA Prescribing Information for this medicine does not include a Boxed Warning. A Boxed Warning (often called a Black Box Warning) is a specific type of warning used by regulatory bodies to highlight serious risks associated with a drug.

Q: Is Brodil Levo known to interact with commonly used cold medicines?

Official drug interaction documents caution against taking this medicine concurrently with other sympathomimetic (adrenergic) drugs. These types of ingredients are often found in common over-the-counter cold and allergy preparations. This caution is advised due to the risk of combined, additive effects on the cardiovascular system.

Q: What kind of follow-up monitoring is suggested when taking Brodil Levo?

Official regulatory guidance suggests that monitoring of certain lab values may be needed when this medicine is used with other specific drugs. For example, monitoring may be considered for potassium levels when taken with non-potassium-sparing diuretics, and Digoxin levels if taken concurrently with that medicine.

Q: Is Brodil Levo a controlled substance?

No, this medicine is not classified as a federally controlled substance. This classification, handled by the DEA (Drug Enforcement Administration) in the US, means it is not controlled due to potential for abuse or dependence.

Official Storage and Disposal Instructions

Brodil Levo must be stored strictly according to regulatory label requirements to maintain its stability. The medication must be kept at controlled room temperature, typically 20 C to 25 C, and stored in a cool and dry place. It is mandatory to protect all forms from light, moisture, and excessive heat. The medication must not be frozen.

For the inhalation solution, vials should remain in their protective foil pouch until use. Once the pouch is opened, remaining vials must be used within two weeks to ensure stability. All forms of Brodil Levo must be stored out of the sight and reach of children.

Disposal of any unused or expired product must be carried out in compliance with Federal, State, and Local regulations. Pressurized aerosol containers must not be punctured or discarded in an incinerator or fire.